Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2012

View Archived Issues

Safety results presented from the AMETHYST-DN study

Scientists at Myrexis synthesize new IKK-epsilon inhibitors

Gilead Sciences patents novel antiviral agents

New vaccines for tuberculosis disclosed by Alarum Development

Genmab presents novel bispecific antibodies for cancer

Allergan patents new S1P1 receptor agonists

Novel agents for HIV infection synthesized by Bristol-Myers Squibb

New antimalarial agents prepared at The Broad Institute

Brodalumab does not demonstrate meaningful clinical efficacy in patients with RA

Antitumor efficacy demonstrated for PF-05082566 in mouse model

Further data published on BAY-1000394

Phase IIb trial of AM-111 in severe hearing loss meets primary endpoint

Japanese team develops novel MAPK inhibitor for autoimmune diseases

Phase III trial of rivaroxaban for secondary prevention of cardiac events begins

PDUFA date set for Lymphoseek NDA resubmission

Interim results for CVax show encouraging immune response

Data monitoring committee recommends continuation of phase I NBTXR-3 trial

Can-Fite BioPharma to develop CF-602 for sexual dysfunction

AtheroNova partner files IND in Russia for AHRO-001

Diazyme obtains FDA clearance for use of kidney disease biomarker test

Bristol-Myers Squibb and AstraZeneca gain European approval for dapagliflozin

Committee recommends completion of PICASSO 3 trial as planned

Transgene and EORTC to collaborate on phase IIb trial of TG-4001

Pacific Therapeutics reports encouraging phase I results with combination treatment for fibrosis

Daiichi Sankyo files application in Japan for use of Inavir in prevention of influenza infection

European orphan product designation granted to algenpantucel-L

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...